Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417761 | 1.00 | MGLL (0.65) | MGLL | |
| SCHEMBL19601848 | 0.92 | MGLL (0.55) | MGLL | |
| SCHEMBL19582632 | 0.89 | MGLL (0.66) | MGLL | |
| SCHEMBL19582478 | 0.87 | MGLL (0.61) | MGLL | |
| SCHEMBL19582667 | 0.85 | MGLL (0.64) | MGLL | |
| SCHEMBL20778404 | 0.83 | MGLL (0.58) | MGLL | |
| SCHEMBL19582311 | 0.82 | MGLL (0.61) | MGLL | |
| SCHEMBL19582555 | 0.82 | MGLL (0.79) | MGLL | |
| SCHEMBL20769614 | 0.81 | MGLL (0.73) | MGLL | |
| SCHEMBL29532195 | 0.81 | MGLL (0.73) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455226-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10781211-B2 | Spirocycle compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781211-B2 | Spirocycle compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3455226-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| WO-2017197192-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781211-B2 | Spirocycle compounds and methods of making and using same | ABHD6, ABHD16A, ACSL6 | MGLL 24/4885 |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, ACSL6 | MGLL 24/4885 |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABHD6, ABHD16A, ACSL6 | MGLL 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.